(Press-News.org) BIRMINGHAM, Ala. – Chronic obstructive pulmonary disease patients with type 2 inflammation may soon gain access to a new drug — dupilumab — that showed rapid and sustained improvements in patients in a pivotal Phase 3 clinical trial, researchers report in the New England Journal of Medicine. This monoclonal antibody is the first biologic shown to improve clinical outcomes in COPD. The data supporting the use of dupilumab in COPD will be reviewed by the United States Food and Drug Administration in June.
The disease improvements — as measured by a significantly lower annualized rate of acute exacerbations and significantly better lung function than placebo-treated adults with COPD — were observed at 12 weeks after the initiation of dupilumab and were sustained throughout the 52-week trial period. In terms of safety, the number of adverse events was similar between placebo and treatment groups and consistent with the established profile of dupilumab.
The lung disease COPD is marked by cough and labored breathing. COPD has traditionally been thought of as an inflammatory disease predominantly driven by neutrophilic inflammation. About 20 percent to 40 percent of COPD patients have COPD with a predominant type 2 inflammation that is commonly detected by elevated blood eosinophil counts. These patients have a high risk of exacerbations.
“Dupilumab substantially decreases exacerbation frequency and improves lung function as well as symptom burden in patients with COPD with type 2 inflammation and high exacerbation risk, who are already on maximal inhaled therapy,” said Surya Bhatt, M.D., a professor of medicine and endowed professor of airways disease in the University of Alabama at Birmingham Department of Medicine Division of Pulmonary, Allergy and Critical Care Medicine.
Bhatt and Klaus Rabe, M.D., Ph.D., a professor of pulmonary medicine at the LungenClinic Grosshansdorf, Grosshansdorf, Germany, co-led the international multicenter clinical study that had 470 patients in the dupilumab group and 465 patients in the placebo group. The patients ranged in age from 40 to 85.
The just completed trial replicates an initial, nearly identical, Phase 3 clinical trial of dupilumab reported in NEJM by Bhatt and Rabe last year. The current Phase 3, randomized, double-blind, placebo-controlled trial was needed to confirm findings of that first trial for COPD patients with blood eosinophil counts of 300 cells per microliter or higher and an elevated exacerbation risk, despite being on inhaled triple therapy. Carefully designed clinical trials produce data that allows the FDA to determine whether benefits of an investigational drug outweigh any known and potential risks for its intended population.
COPD patients often have disease exacerbations that can lead to an increased risk of subsequent exacerbations, accelerated lung-function decline and an increased risk of death. Thus, says Bhatt, improving lung function and reducing exacerbations are unmet needs in patients with COPD.
“COPD is the third leading cause of death globally,” Bhatt said. “Exacerbations of COPD lead to poorer quality of life, increased hospitalizations and an increased risk of death.”
Support came from Sanofi and Regeneron Pharmaceuticals Inc.
Study results were presented at the May 2024 American Thoracic Society International Conference in San Diego, California, and simultaneously published in the New England Journal of Medicine.
At UAB, Medicine is a department in the Marnix E. Heersink School of Medicine.
END
Second Phase 3 clinical trial again shows dupilumab lessens disease in COPD patients with type 2 inflammation
Chronic obstructive pulmonary disease patients with type 2 inflammation saw rapid and sustained improvements after treatment with the monoclonal antibody dupilumab.
2024-05-20
ELSE PRESS RELEASES FROM THIS DATE:
Autoimmune disease not associated with monoclonal gammopathy
2024-05-20
Embargoed for release until 5:00 p.m. ET on Monday 20 May 2024
Annals of Internal Medicine Tip Sheet
@Annalsofim
Below please find summaries of new articles that will be published in the next issue of Annals of Internal Medicine. The summaries are not intended to substitute for the full articles as a source of information. This information is under strict embargo and by taking it into possession, media representatives are committing to the terms of the embargo not only on their own behalf, but also on behalf of the organization they represent.
----------------------------
1. ...
Purdue-led fishing expedition nets new pupfish family member in New Mexico
2024-05-20
Purdue-led fishing expedition nets new pupfish family member in New Mexico
Genetic drift, not natural selection, identified as main factor driving speciation
WEST LAFAYETTE, Ind. Scientists have identified a new member on the genetic family tree of an endangered pupfish native to south-central New Mexico.
“We went into this thinking that there was one species of conservation concern,” said J. Andrew DeWoody, professor of genetics in Purdue University’s Department of Forestry and Natural Resources. “The preponderance of evidence ...
Yoga and meditation-induced altered states of consciousness are common in the general population
2024-05-20
BOSTON--Yoga, mindfulness, meditation, breathwork, and other practices are gaining in popularity due to their potential to improve health and well-being. The effects of these practices are mostly positive and occasionally transformational, yet they are known to sometimes be associated with challenging altered states of consciousness.
New research by a team including investigators from Massachusetts General Hospital, a founding member of the Mass General Brigham healthcare system, reveals that altered states of consciousness associated with meditation practice are far more common than expected.
Although many people reported positive outcomes, that were sometimes even considered ...
UCF researcher is developing algorithms to further space, sea exploration
2024-05-20
Cislunar space, which stretches from the Earth to just beyond the moon’s orbit, is about to become heavily trafficked over the next 10 years. With NASA’s planned Artemis missions and other countries joining in the cislunar space race, there’s an interest in observing, tracking and predicting the orbit of objects like asteroids and satellites so they don’t collide with spacecraft.
But the process of detecting and observing space objects, known as space domain awareness (SDA), faces challenges with the extensive volume of cislunar space.
“Cislunar space is vast,” says Tarek Elgohary, an associate professor ...
Illuminating neuro-vascular dynamics throughout the body: 3D-printed implants and bioluminescence duet shed light on brain–spinal interactions
2024-05-20
A sensory process such as pain is no ordinary phenomenon—it’s a symphony of neural and vascular interactions orchestrated by the brain and spinal cord. Attempting to dissect this symphony by focusing on a single region is like trying to understand a complex melody by listening to just one instrument. It’s incomplete, potentially misleading, and may result in erroneous conclusions.
Enter the Carney Institute’s team of visionaries. Their mission? To develop tools that allow unprecedented observation of neural and vascular activity within the brain and spinal cord. They tackled two critical fronts: imaging hardware and bioluminescent (BL) molecular tools.
Innovative ...
Studies show linked biological pathways driving skin inflammation
2024-05-20
A certain biological pathway, a set of linked reactions in the body, drives the inflammation seen in the skin disease psoriasis, a new study finds. The work could lead to improved therapies for all inflammatory skin diseases, including atopic and allergic dermatitis and a type of boil called hidradenitis suppurativa, say the study authors. Inflammation is the body’s natural response to irritation and infection, but when out of control, it can lead to the reddish, flaky, itchy lesions that come with these skin diseases.
Led by researchers at NYU Langone Health, the new study found that the interleukin-17 (IL-17) pathway, ...
Fowler awarded 2023 NASA Planetary Science Early Career Award
2024-05-20
Research Assistant Professor Christopher Fowler received the NASA 2023 Planetary Science Early Career Award for his project “Bringing Planetary Science to West Virginia”. The award is based on demonstrated leadership, involvement in the planetary science community, and potential for future impact.
The resources provided by the NASA Planetary Science Early Career Award will allow Fowler and team to undertake research-related activities that are not always possible within the scope of more “traditional” ...
Anticancer potential of CLK kinase inhibitors 1C8 and GPS167 via EMT and antiviral immune response
2024-05-20
“[...] we have characterized a pair of compounds that impact multiple processes that are relevant to cancer cell proliferation but also, and possibly more importantly, to metastasis [...].”
BUFFALO, NY- May 20, 2024 – A new research paper was published in Oncotarget's Volume 15 on May 16, 2024, entitled, “The anticancer potential of the CLK kinases inhibitors 1C8 and GPS167 revealed by their impact on the epithelial-mesenchymal transition and the antiviral immune response.”
The diheteroarylamide-based compound 1C8 and the aminothiazole carboxamide-related compound GPS167 inhibit the CLK kinases, and affect ...
Aging contributes to 2024 Systems Aging Gordon Research Conference
2024-05-20
Aging is contributing at the 2024 Systems Aging Gordon Research Conference in Barcelona, Spain, from June 2–7.
BUFFALO, NY- May 20, 2024 – Aging is a contributor at the 2024 Systems Aging Gordon Research Conference (GRC) on “Systems Modeling, Aging Biomarkers, and Longevity Interventions” — taking place from June 2–7, 2024, in Castelldefels, Barcelona, Spain.
“The conference will present recent advances in systemic rejuvenation, multi-omics approaches, applications ...
Pioneering research study makes significant contributions toward addressing the shortage of suitable knee meniscus and TMJ disc replacements
2024-05-20
The shortage of suitable donor meniscus grafts from the knee and temporomandibular joint (TMJ) impedes treatments for millions of patients. Vitrification offers a promising solution by transitioning these tissues into a vitreous state at cryogenic temperatures, protecting them from ice crystal damage using high concentrations of cryoprotectant agents (CPAs). However, vitrification's success is hindered for larger tissues (>3 mL) due to challenges in CPA penetration. Dense avascular meniscus tissues require extended CPA exposure for adequate penetration; however, ...
LAST 30 PRESS RELEASES:
iRECODE: A new computational method that brings clarity to single-cell analysis
New NUS-MOH study: Singapore’s healthcare sector carbon emissions 18% lower than expected, a milestone in the city-state’s net zero journey
QUT scientists create material to turn waste heat into clean power
Major new report sets out how to tackle the ‘profound and lasting impact’ of COVID-19 on cardiovascular health
Cosmic crime scene: White dwarf found devouring Pluto-like icy world
Major report tackles Covid’s cardiovascular crisis head-on
A third of licensed GPs in England not working in NHS general practice
ChatGPT “thought on the fly” when put through Ancient Greek maths puzzle
Engineers uncover why tiny particles form clusters in turbulent air
GLP-1RA drugs dramatically reduce death and cardiovascular risk in psoriasis patients
Psoriasis linked to increased risk of vision-threatening eye disease, study finds
Reprogramming obesity: New drug from Italian biotech aims to treat the underlying causes of obesity
Type 2 diabetes may accelerate development of multiple chronic diseases, particularly in the early stages, UK Biobank study suggests
Resistance training may improve nerve health, slow aging process, study shows
Common and inexpensive medicine halves the risk of recurrence in patients with colorectal cancer
SwRI-built instruments to monitor, provide advanced warning of space weather events
Breakthrough advances sodium-based battery design
New targeted radiation therapy shows near-complete response in rare sarcoma patients
Does physical frailty contribute to dementia?
Soccer headers and brain health: Study finds changes within folds of the brain
Decoding plants’ language of light
UNC Greensboro study finds ticks carrying Lyme disease moving into western NC
New implant restores blood pressure balance after spinal cord injury
New York City's medical specialist advantage may be an illusion, new NYU Tandon research shows
Could a local anesthetic that doesn’t impair motor function be within reach?
1 in 8 Italian cetacean strandings show evidence of fishery interactions, with bottlenose and striped dolphins most commonly affected, according to analysis across four decades of data and more than 5
In the wild, chimpanzees likely ingest the equivalent of several alcoholic drinks every day
Warming of 2°C intensifies Arctic carbon sink but weakens Alpine sink, study finds
Bronze and Iron Age cultures in the Middle East were committed to wine production
Indian adolescents are mostly starting their periods at an earlier age than 25 years ago
[Press-News.org] Second Phase 3 clinical trial again shows dupilumab lessens disease in COPD patients with type 2 inflammationChronic obstructive pulmonary disease patients with type 2 inflammation saw rapid and sustained improvements after treatment with the monoclonal antibody dupilumab.